To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. If you experience any issues, please contact ATCC Customer Service at For Technical questions please contact Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.

Pseudomonas aeruginosa (Schroeter) Migula (ATCC® BAA-2108)

Strain Designations: PGO2330  /  Type Strain: no  /  Biosafety Level: 2

Permits and Restrictions

View Permits

Strain Designations PGO2330
Sputum sample, human
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Product Format frozen
Storage Conditions Frozen: -80°C or colder
Freeze-Dried: 2°C to 8°C
Live Culture: See Propagation Section
Preceptrol® no
Type Strain no
Antibiotic Resistance Multidrug-resistant
This isolate was collected from a sputum sample of a cystic fibrosis patient during a Phase III clinical trial that tested the effectiveness of aerosolized Tobi (Tobramycin). The 1995-1996 clinical trial was conducted by a consortium led by Chiron and later acquired by Novartis AG.
Medium ATCC® Medium 18: Trypticase Soy Agar/Broth
Growth Conditions
Temperature: 37°C
Atmosphere: Aerobic
Name of Depositor Chiron/Novartis
Sputum sample, human

Ramsey BW, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328(24): 1740-1746, 1993. PubMed: 8497284

Burns JL, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27(1): 158-163, 1998. PubMed: 9675470

Burns JL, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5): 1190-1196, 1999. PubMed: 10191222

Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 120(3 Suppl): 107S-113S, 2001. PubMed: 11555564

Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 121(1): 55-63, 2002. PubMed: 11796432

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation